Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abzena Cambridge Ltd
Original Assignee
Antitope Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antitope LtdfiledCriticalAntitope Ltd
Application grantedgrantedCritical
Publication of ES2366971T3publicationCriticalpatent/ES2366971T3/es
APL1, an altered peptide ligand derived from human heat-shock protein 60, increases the frequency of Tregs and its suppressive capacity against antigen responding effector CD4+ T cells from rheumatoid arthritis patients
Human subjects without peanut allergy demonstrate T cell–dependent, TH2-biased, peanut-specific cytokine and chemokine responses independent of TH1 expression
Heterogeneity of magnitude, allergen immunodominance, and cytokine polarization of cockroach allergen‐specific T cell responses in allergic sensitized children